ArticleFrontiers in pharmacology2023

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.

Yefan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.